Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

Immunotherapy has been incorporated into the first- and second-line treatment strategies for non-small cell lung cancer (NSCLC), profoundly ushering in a new treatment landscape. However, both adaptive signali...

Source: Molecular Cancer - September 16, 2019 Category: Cancer & Oncology Authors: Anqi Lin, Ting Wei, Hui Meng, Peng Luo and Jian Zhang Tags: Review Source Type: research